Recursion Doses First Patient in Phase 2 Study of REC-994 for Cerebral Cavernous Malformation

Recursion, a company focused on using technology to accelerate drug discovery, has announced that the first patient has been dosed in their Phase 2 clinical trial. This study is evaluating the effectiveness of REC-994, a drug aimed at treating cerebral cavernous malformation (CCM), a condition characterized by abnormal blood vessels in the brain that can lead to seizures, strokes, and other serious neurological issues. The dosing of the first patient marks a significant milestone in the development of potential treatments for this challenging condition.

The Phase 2 trial will assess the safety, tolerability, and efficacy of REC-994 in patients with symptomatic CCM. Recursion is hopeful that this drug can provide a much-needed therapy for those affected by this rare and debilitating disease. The company’s approach, leveraging machine learning and advanced computational techniques, allows for a more efficient and thorough investigation of potential treatments like REC-994.

Recursion's CEO expressed excitement about reaching this stage, emphasizing the potential impact of their drug discovery platform on rare diseases like CCM. The company’s focus on blending technology with biology is paving the way for innovative treatments that could make a real difference in patients' lives. The progress of this trial will be closely monitored as Recursion continues to push forward in its mission to revolutionize the way rare diseases are treated.